Clinical Trials

Your current location:

Home > Clinical Trials > Research Center

Pipeline

Process

Candidates

Indication

Pre-clinical

IND

Doses Escalation (Phase I)

Doses Extension (Phase II)

Protal Study
(Phase III)

Oncolytic virus
BS001(CN)

Melanoma

GBM

mCRC

Others

BS001(US)

Melanoma with αPD-1 failure

BS001 combo with αPD-1 (CN)

mCRC

Sarcoma

BS006(CN)

Solid tumors(IIT)

BS006(US)

Solid tumors

Cell therapy
VAK(CN)

Malignant pleural and abdominal effusions(IIT)

VAK(US)

Malignant pleural and abdominal effusions(IIT)

Note:BS001:oHSV2hGM-CSF,also named OH2 injection;BS006: oHSV2CD3-PD-L1; BS008 (Cocktail): BS001+BS006

Research

Center

Nansha Islands

Introduction to Clinical Centers

The clinical trials of oncolytic type II herpes simplex virus OH2 injection (BS001) monotherapy/combination therapy have been conducted in 20+ research centers (hospitals) in China, 400+ subjects were enrolled for various indications.

Purchase

Top